Sangamo Reclaims Rights to Hemophilia Gene Therapy from Pfizer
Sangamo Therapeutics regains rights to giroctocogene fitelparvovec after Pfizer's successful Phase 3 trials, marking a pivotal shift in hemophilia gene therapy.
Topic
gene therapy
A collection of 6 issues
Pfizer Ends Partnership with Sangamo on Hemophilia A Therapy
Pfizer terminates its partnership with Sangamo, citing limited interest in advancing another hemophilia A gene therapy. Explore the implications for biotech innovation.
Sangamo Stock Drops 67% After Pfizer Partnership Ends
Sangamo Therapeutics' shares nosedived by 67% following Pfizer's decision to terminate their hemophilia A gene therapy collaboration. Explore the impact on biotech stocks.
Pfizer Opts Out of New Hemophilia A Gene Therapy
Pfizer pulls back on developing a new gene therapy for hemophilia A, citing limited market interest. Explore the implications for the hemophilia community and biotech sector.
Sangamo Therapeutics Stock Plummets 67% After Pfizer Ends Hemophilia A Partnership
Sangamo Therapeutics Inc. stock dropped 67% as Pfizer Inc. terminated its collaboration on gene therapy for hemophilia A, impacting Sangamo's financial outlook.
Sangamo Shares Plunge After Pfizer Ends Gene Therapy Deal
Sangamo stock drops sharply as Pfizer terminates collaboration on hemophilia A gene therapy. Explore the impact on Sangamo's market position and future plans.